<- Go Home
RayzeBio, Inc.
RayzeBio, Inc. operates as a biotechnology company developing targeted radiopharmaceutical therapies for cancer treatment. The company focuses on solid tumor targets and develops novel drug conjugates designed to deliver therapeutic radioisotopes, such as actinium-225. Its lead clinical program, RYZ101 (AC225 DOTATATE), is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors and extensive stage small cell lung cancer. The company operates a radiopharmaceutical research facility supporting the discovery and development of new drug candidates and conducts preclinical and clinical research programs to evaluate multiple tumor-specific targets for radiotherapy. The company was founded in 2020 and is based in San Diego, California. RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Market Cap
$3.7B
Volume
785.8K
Cash and Equivalents
$252.0M
EBITDA
-$73.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$62.51
52 Week Low
$17.95
Dividend
N/A
Price / Book Value
6.50
Price / Earnings
-7.13
Price / Tangible Book Value
6.50
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$75.7M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$540.2M
Debt
$9.7M
Equity
$575.3M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A